Detalhe da pesquisa
1.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729154
2.
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Cancer
; 119(14): 2611-9, 2013 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23605952
3.
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Invest New Drugs
; 31(2): 370-80, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22661287
4.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(5): 661-674, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271377
5.
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Eur J Cancer
; 127: 52-66, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31986450
6.
Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia.
Oncotarget
; 8(61): 102948-102964, 2017 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29262536
7.
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
Clin Lymphoma Myeloma Leuk
; 13(5): 559-67, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23763917
8.
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
J Clin Oncol
; 27(15): 2523-9, 2009 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19332730